REGISTRY TO EVALUATE EFFECTIVENESS AND SAFETY OF THE NANOKNIFE SYSTEM FOR THE ABLATION OF STAGE 3 PANCREATIC ADENOCARCINOMA
Registry Study to Evaluate the Nanoknife System in Treating Stage 3 Pancreatic Adenocarcinoma
Sponsor: ANGIODYNAMICS
Enrolling: Male and Female Patients
IRB Number: AAAS7037
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to evaluate how safe and effective the NanoKnife System is at treating Stage 3 pancreatic adenocarcinoma. This is registry study and therefore, the NanoKnife System is not being used for study purposes. The safety and efficacy of this system will be evaluated by comparing survival rates, pain ratings, and number of adverse events between a group of subjects who receive treatment with the NanoKnife System, and a group of subjects who receive standard of care treatment for their disease.
Investigator
Michael Kluger, MD, MPH
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with Stage 3 pancreatic cancer? Yes No
Have you received 3 months of standard of care treatment for your disease already? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162